S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
The single greatest medical breakthrough of all time? (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Why Your IRA Could Crash on January 16th? (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Why Your IRA Could Crash on January 16th? (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities

Lyell Immunopharma - LYEL Stock Forecast, Price & News

$3.85
-0.08 (-2.04%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.83
$4.01
50-Day Range
$3.85
$8.09
52-Week Range
$3.57
$10.33
Volume
723,336 shs
Average Volume
1.04 million shs
Market Capitalization
$959.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33

Lyell Immunopharma MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
116.5% Upside
$8.33 Price Target
Short Interest
Bearish
23.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$71,040 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.00) to ($1.22) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

771st out of 1,027 stocks

Pharmaceutical Preparations Industry

377th out of 503 stocks

LYEL stock logo

About Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Stock News Headlines

FDA Approves Lyell Immunopharma's IND For LYL845; Shares Up 8%
LYEL Lyell Immunopharma, Inc.
Lyell Immunopharma Climbs 13% In Morning Trade
See More Headlines
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Company Calendar

Last Earnings
11/08/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LYEL
Fax
N/A
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.33
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+116.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-250,220,000.00
Net Margins
-660.62%
Pretax Margin
-660.62%

Debt

Sales & Book Value

Annual Sales
$10.65 million
Book Value
$3.88 per share

Miscellaneous

Free Float
185,000,000
Market Cap
$959.91 million
Optionable
Not Optionable
Beta
-2.13

Key Executives

  • Dr. Richard D. Klausner M.D. (Age 70)
    Founder & Exec. Chairman
    Comp: $510.17k
  • Ms. Elizabeth Homans (Age 56)
    CEO & Director
    Comp: $988.85k
  • Mr. Charles W. Newton (Age 51)
    Chief Financial Officer
    Comp: $1.75M
  • Mr. Stephen J. Hill (Age 52)
    Chief Operating Officer
    Comp: $808.12k
  • Prof. Stanley R. Riddell M.D.
    Founder & Scientific Advisor
  • Dr. Crystal L. Mackall M.D.
    Founder & Scientific Advisor
  • Nellie Dillery
    Director of Accounting
  • Mr. Richard Goold Ph.D. (Age 62)
    Chief Information Officer
  • Dr. Gary Lee Ph.D. (Age 45)
    Chief Scientific Officer
  • Ellen Rose
    VP of Communications & Investor Relations













LYEL Stock - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares.
View LYEL analyst ratings
or view top-rated stocks.

What is Lyell Immunopharma's stock price forecast for 2023?

3 brokers have issued 1 year price targets for Lyell Immunopharma's shares. Their LYEL share price forecasts range from $7.00 to $11.00. On average, they expect the company's share price to reach $8.33 in the next year. This suggests a possible upside of 116.5% from the stock's current price.
View analysts price targets for LYEL
or view top-rated stocks among Wall Street analysts.

How have LYEL shares performed in 2022?

Lyell Immunopharma's stock was trading at $7.74 at the start of the year. Since then, LYEL stock has decreased by 50.3% and is now trading at $3.85.
View the best growth stocks for 2022 here
.

When is Lyell Immunopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our LYEL earnings forecast
.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings results on Tuesday, November, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. Lyell Immunopharma had a negative trailing twelve-month return on equity of 29.54% and a negative net margin of 660.62%.

When did Lyell Immunopharma IPO?

(LYEL) raised $425 million in an IPO on Thursday, June 17th 2021. The company issued 25,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.

What is Lyell Immunopharma's stock symbol?

Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."

Who are Lyell Immunopharma's major shareholders?

Lyell Immunopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.98%), BlackRock Inc. (4.70%), Foresite Capital Management IV LLC (4.01%), Alphabet Inc. (2.35%), State Street Corp (2.16%) and Price T Rowe Associates Inc. MD (2.13%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends
.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyell Immunopharma's stock price today?

One share of LYEL stock can currently be purchased for approximately $3.85.

How much money does Lyell Immunopharma make?

Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $959.91 million and generates $10.65 million in revenue each year. The company earns $-250,220,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does Lyell Immunopharma have?

The company employs 219 workers across the globe.

How can I contact Lyell Immunopharma?

The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com.

This page (NASDAQ:LYEL) was last updated on 12/8/2022 by MarketBeat.com Staff